Literature DB >> 12887529

Alternative sites of injection for sentinel lymph node biopsy in breast cancer.

Liesl Celliers1, G Bruce Mann.   

Abstract

BACKGROUND: Sentinel node biopsy is rapidly gaining popularity as a less invasive approach to nodal staging in breast cancer. The optimal route of injection of radiocolloids and dye is controversial. The purpose of the present paper was to review and assess the literature.
METHODS: A MEDLINE search for reports of studies involving different injection sites of colloid and/or dye was performed.
RESULTS: Although controversial, current evidence suggests that subareolar (SA) or intradermal/subdermal (ID/SD) injection will map the same axillary sentinel nodes (SN) as peritumoral (PT) injection in the vast majority of cases, is at least as successful, and is better logistically. Peritumoral, but not alternative routes, identify extra-axillary sentinel nodes, which are important in a minority of patients.
CONCLUSIONS: It is recommended that at least some of the radiocolloid be injected peritumorally to avoid missing those SN not located in the ipsilateral axilla. Injection of the dye and a portion of radiocolloid in an ID/SA location is reasonable to take advantage of the general ease and accuracy of ID/SA injections in identifying axillary SN.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12887529     DOI: 10.1046/j.1445-2197.2003.02705.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  2 in total

1.  Efficacy of Periareolar Versus Peritumoral Injection of TC99-Labelled Sulphur Colloid and Methylene Blue Dye for Detection of Sentinel Lymph Node in Patients with Early Breast Cancer: a Comparative Study.

Authors:  Chanchal Malhotra; Richa Pawar; Sanjeev Patni; Mitesh Kaushik; Nivedita Sharma
Journal:  Indian J Surg Oncol       Date:  2020-09-25

2.  The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study.

Authors:  Hiroo Suami; Wei-Ren Pan; G Bruce Mann; G Ian Taylor
Journal:  Ann Surg Oncol       Date:  2007-11-28       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.